Published Online: Saturday, July 1, 2006

Incentives built into the new Medicare Part D drug plan to increase the use of generic drugs are driving down program costs significantly, according to the results of a new study. Researchers at Verispan found that 55% of all prescriptions being filled by Medicare patients during the first 3 months of the new program were for generic drugs.

Teva Pharmaceuticals was the leading supplier of drugs for Medicare recipients enrolled in Part D. Four other generic manufacturers—Mylan Pharmaceuticals, Watson Pharmaceuticals Inc, IVAX Pharmaceuticals Inc, and Mallinckrodt Medical—also ranked among the top 10, the researchers said.

Latest Articles
This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings and more.
Chronic kidney disease incidence has grown faster than many of its common comorbidities such as diabetes and hypertension, and medications may be an underappreciated driver of this growth.
President Barack Obama’s fiscal year 2017 budget proposal calls for an additional $1.1 billion to combat the nation’s spiraling opioid epidemic.
Baxter International is voluntarily recalling intravenous solution due to leaking containers and the potential for particulate matter.
Latest Issues